News & Updates
Filter by Specialty:
Tocilizumab trumps etanercept at suppressing RA joint erosion
Treatment with tocilizumab leads to better suppression of joint erosion progression as compared to etanercept in patients with rheumatoid arthritis (RA), reports a recent study.
Tocilizumab trumps etanercept at suppressing RA joint erosion
25 Oct 2022
Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
The use of vedolizumab in the treatment of older patients with inflammatory bowel disease (IBD) appears to not only pose a higher risk of treatment failure but also offer no significant safety advantage when compared with tumour necrosis factor (TNF) antagonists, according to a study.
Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
25 Oct 2022
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
Sequential intravesical valrubicin and docetaxel prove to be an effective salvage treatment for patients with recurrent nonmuscle-invasive bladder cancer (NMIBC), a study has shown.
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
24 Oct 2022
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
23 Oct 2022
Long-term tapinarof use proven safe, effective in plaque psoriasis
Continuous and intermittent use of tapinarof cream 1% once daily (QD) for up to 1 year is effective in patients with mild-to-severe plaque psoriasis, without serious safety concerns, according to a study. In addition, it has shown durable efficacy and a remittive effect of at least 4 months off therapy.
Long-term tapinarof use proven safe, effective in plaque psoriasis
21 Oct 2022
Amphilimus- vs zotarolimus-eluting stents: Any preference in patients with diabetes?
Updated results of the SUGAR* trial showed that using polymer-free amphilimus-eluting stents (AES) was not a superior option to durable-polymer zotarolimus-eluting stents (ZES) in patients with diabetes mellitus who required percutaneous coronary intervention (PCI).